Champions Oncology, Inc. (CSBR): Joel Ackerman , Chief Executive Officer of Champions Oncology, Inc. purchased 33 shares on Sep 23, 2016. The Insider buying transaction was reported by the company on Sep 26, 2016 to the Securities and Exchange Commission. The shares were purchased at $1.65 per share for a total value of $54.45 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 21, 2016, Ronnie Morris (President) purchased 3,000 shares at $1.58 per share price.On Sep 21, 2016, Joel Ackerman (CEO) purchased 5,000 shares at $1.66 per share price.Also, On Mar 17, 2015, Daniel Newman Mendelson (director) purchased 750,000 shares at $0.00 per share price.
Champions Oncology Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The Company’s POS business provides services to physicians and patients looking for information to help guide the development of personalized treatment plans. The Company’s TOS business provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. The Company’s TumorGraft Technology Platform consists of processes physical tumors and information that it uses to personalize the development and use of oncology drugs.